Sort   by:  
 Page size 
ProteomicsLanifibranor reduces inflammation and improves dyslipidemia in lysosomal acid lipase-deficient mice
Background & Aims Recent studies showed that patients suffering from lysosomal acid lipase-deficiency (LAL-D) benefit tremendously from enzyme replacement therapy (ERT), however, the outcomes on liver histology in treated patients were inconsistent. The promising results of the pan-PPAR agonist lani...
ORGANISM(S): Mus musculus (Mouse) 
2024-06-12 | PXD047957 | Pride
Pan-ppar agonist Proteomics Lipid metabolism Lysosomal acid lipase deficiency Liver inflammation Plasma lipoproteins Lanifibranor 
UnknownLanifibranor Reduces Inflammation and Improves Dyslipidemia in Lysosomal Acid Lipase-Deficient Mice.
Not available
S-EPMC11401563 | biostudies-literature
UnknownThe pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis.
Not available
S-EPMC11087475 | biostudies-literature
GenomicsHepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
PRJNA807693 | ENA
TranscriptomicsHepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH
Non-alcoholic steatohepatitis (NASH) has emerged as a major challenge for public health because of high global prevalence and lack of evidence-based therapies. Most animal models of NASH lack sufficient validation regarding disease progression and pharmacological treatment. The Gubra-Amylin NASH (GA...
ORGANISM(S): Mus musculus 
2022-02-21 | GSE196908 | GEO
UnknownFunctional and Structural Insights into the Human PPARα/δ/γ Targeting Preferences of Anti-NASH Investigational Drugs, Lanifibranor, Seladelpar, and Elafibranor.
Not available
S-EPMC10451623 | biostudies-literature
UnknownHepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.
Not available
S-EPMC9099137 | biostudies-literature
TranscriptomicsHepatoprotective effects of late-stage clinical drug candidates and dietary intervention in the non-obese CDAA-HFD mouse model of advanced MASH with progressive fibrosis
We applied RNA sequencing (RNA-seq) to study the gene expression profile in the liver of mice fed the CDAA-HFD for 3 weeks (n=9), 6 weeks (n=10), 12 weeks (n=8) and 20 weeks (n=8) and lean chow controls (n=8). At all timepoints, CDAA-HFD mice displayed a widespread increase in the expression of MASH...
ORGANISM(S): Mus musculus 
2024-10-10 | GSE269493 | GEO
UnknownAltered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment
Not available
S-EPMC12142333 | biostudies-literature
UnknownSemaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.
Not available
S-EPMC10754821 | biostudies-literature
Sort   by:  
 Page size